Skip to content

A pilot study for Echinocandins combination with trimethoprim/sulfamethoxazole and clindamycin in the treatment of AIDS patients with pneumocystis pneumonia

A pilot study for Echinocandins combination with trimethoprim/sulfamethoxazole and clindamycin in the treatment of AIDS patients with pneumocystis pneumonia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018827
Enrollment
Unknown
Registered
2018-10-12
Start date
2018-10-12
Completion date
Unknown
Last updated
2018-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumocystis pneumonia patients infected with HIV

Interventions

Two cohorts (PaO2/FiO2>200mmHg, or <200mmHg):Combined echinocandin treatment

Sponsors

the First Affiliated Hospital, College of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) AIDS diagnosis is clear; (2) aged = 18 years old; (3) initial treatment; (4) compliance with PCP diagnosis.

Exclusion criteria

Exclusion criteria: (1) patients who are receiving HAART at the time of onset; (2) combined with other immunocompromised diseases such as tumors, congenital, after chemotherapy, etc.; (3) IRIS patients; (4) severe allergies and/or Those who are allergic to sulfa drugs; (5) those with serious heart, brain, liver, kidney and other important organ diseases, severe blood, endocrine system diseases and medical history.

Design outcomes

Primary

MeasureTime frame
Oxygenation index;

Countries

China

Contacts

Public ContactBiao Zhu

the First Affiliated Hospital, College of Medicine, Zhejiang University

zhubiao1207@zju.edu.cn+86 13906535457

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026